PD-1/PD-L1
|
CPI
|
NCT02807636
(IMvigor130)
|
Untreated mUC
|
Atezolizumab
|
Atezolizumab + (Carboplatin)
(Gemcitabine)
(Cisplatin)
|
Phase III
|
November 2020
|
NCT02853305
(Keynote-361)
|
Untreated mUC
|
Pembrolizumab
|
Pembrolizumab + (Cisplatin)
(Carboplatin)
(Gemcitabine)
|
Phase III
|
May 2020
|
CTLA-4
|
NCT02516241
(DANUBE)
|
Untreated mUC
|
Tremelimumab
|
Durvalumab + tremelimumab or durvalumab monotherapy
|
Phase III
|
September 2019
|
CD122
|
Cytokine Modulation
|
NCT02983045
(PIVOT-2)
|
Advanced tumors (mUC)
|
NKTR-214
|
NKTR-214 + nivolumab or NKTR-214 + nivolumab + ipilimumab
|
Phase I/II
|
June 2021
|
NCT03785925
(Pivot-10)
|
Cisplatin-ineligible, mUC patients with low PD-L1 expression
|
NKTR-214
|
NKTR-214 + nivolumab
|
Phase III
|
May 2022
|
NCT03138889
(PROPEL)
|
Advanced tumors (mUC)
|
NKTR-214
|
NKTR-214 + pembrolizumab or NKTR-214 + atezolizumab
|
Phase I
|
May 2020
|
IL-7
|
NCT03513952
|
Advanced, inoperable or mUC
|
CYT107
|
CYT107 + atezolizumab
|
Phase I
|
December 2020
|
TGFβ + PD-1
|
NCT02517398
|
Advanced tumors (mUC)
|
MSB0011359C (M7824)
|
MSB0011359C (M7824)
|
Phase I
|
August 2020
|
CD137/4-1BB
|
NCT02845323
|
Cisplatin-ineligible MIBC
|
Urelumab
|
Urelumab + nivolumab or nivolumab monotherapy
|
Phase II
|
January 2020
|
OX40
|
NCT02554812
(JAVELIN Medley)
|
Advanced tumors (mUC)
|
PF-04518600
|
Avelumab
Utomilumab
PF-04518600
PD 0360324
|
Phase II
|
December 2020
|
NCT03217747
|
Advanced tumors (UC)
|
PF-04518600
|
Avelumab
UtomilumabPF-04518600
Radiation
Cisplatin
|
Phase I/II
|
August 2023
|
IDO
|
T Cell Metabolism
|
NCT03361865
(Keynote-672)
(ECHO307)
|
Cisplatin-ineligible UC
|
Epacadostat
|
Epacadostat + pembrolizumab
|
Phase III
|
September 2020
|
NCT03374488
(Keynote-698)
|
Cisplatin-ineligible mUC
|
Epacadostat
|
Epacadostat + pembrolizumab
|
Phase III
|
August 2020
|
VEGF
|
TKI
|
NCT03133390
|
Cisplatin-ineligible mUC
|
Bevacizumab
|
Bevacizumab + atezolizumab
|
Phase II
|
January 2020
|
NCT03272217
|
Cisplatin-ineligible untreated mUC
|
Bevacizumab
|
Bevacizumab + atezolizumab
|
Phase II
|
April 2021
|
cMET/VEGF
|
NCT02717156
|
Untreated mUC
|
EphB4-HSA
|
EphB4-HAS + pembrolizumab
|
Phase II
|
November 2020
|
NCT03534804
(PemCab)
|
Cisplatin-ineligible mUC
|
Cabozantinib
|
Cabozantinib + pembrolizumab
|
Phase II
|
September 2023
|
NCT03170960
|
Advanced tumors (UC)
|
Cabozantinib
|
Cabozantinib + atezolizumab
|
Phase I/II
|
December 2020
|
FGFR
|
NCT02546661
(BISCAY)
|
Previously-treated MIBC
|
AZD4547
MEDI4736
Olaparib
AZD1775
Vistusertib
AZD9150
Selumetinib
|
Phase Ib
|
March 2020
|
NCT03123055
(FIERCE-22)
|
mUC
|
Vofatamab
|
Vofatamab + pembrolizumab
|
Phase I/II
|
September 2022
|
NCT03473756
(FORT-2)
|
FGFR-positive mUC
|
Rogaratinib
|
Rogaratinib + atezolizumab
|
Phase Ib/II
|
July 2022
|
Nectin-4
|
ADC
|
NCT03288545
(EV-103)
|
mUC
|
Enfortumab Vedotin
|
Enfortumab vedotin + pembrolizumab
|
Phase I
|
September 2024
|
NCT03219333
(EV-201)
|
mUC previously-treated with CPI
|
Enfortumab Vedotin
|
Enfortumab vedotin
|
Phase II
|
May 2025
|
NCT02091999
|
Nectin-4-positive mUC
|
Enfortumab Vedotin
|
Enfortumab vedotin
|
Phase I
|
December 2020
|
NCT03474107
(EV-301)
|
Previously-treated mUC
|
Enfortumab Vedotin
|
Enfortumab vedotin
|
Phase III
|
September 2021
|
HER-2
|
NCT03523572
|
mUC
|
Trastuzumab Deruxtecan
(DS-8201a)
|
Trastuzumab
Deruxtecan
(DS-8201a)
|
Phase I/II
|
September 2020
|